“This drug delivery system is DNA-based, which means it is biocompatible and less toxic to patients than systems that use synthetic materials,” says Dr. Zhen Gu, senior author of a paper on the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. …
In a paper published today in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs. The new drug works by stopping a key process that allows cancer cells to multiply…
Especially the localization wire. A localization wire literally is a thin wire inserted into the breast through a needle to help mark the location of a tumor or benign mass on the day of surgery…
In the future, the newly developed technique will enable increasingly accurate image acquisition especially during PET scans performed to detect cancers of the chest and upper abdomen, and inflammatory diseases of the heart. PET scanning, or positron emission tomography, is a modern nuclear medicine imaging method, which allows for the detection of cancer and heart conditions. Thanks to enhanced image quality, PET images provide new and increasingly accurate data, potentially improving diagnosis reliability and treatment response monitoring. High-quality image data makes the treatment more efficient both medically and financially. …
The so-called Signal Transducers and Activators of Transcription, or STATs, are key components of many different signalling pathways. Not surprisingly, then, when something goes wrong with their regulation the consequences can be severe and many types of cancer are known to be associated with increased activities of one or more STAT protein. STAT3 is a frequent culprit and is often found to be activated in tumour cells. Considerable efforts are going into developing inhibitors of STAT3 for use in cancer therapy but it is unclear whether these will turn out to be suitable for use in patients. …
“While laboratory studies support an important role for cholesterol in prostate cancer, population-based evidence linking cholesterol and prostate cancer is mixed,” said Emma Allott, PhD, postdoctoral associate at Duke University School of Medicine in Durham, North Carolina. “Understanding associations between obesity, cholesterol, and prostate cancer is important given that cholesterol levels are readily modifiable with diet and/or statin use, and could therefore have important, practical implications for prostate cancer prevention and treatment. “Our findings suggest that normalization, or even partial normalization, of serum lipid levels among men with dyslipidemia [abnormal lipid profile] may reduce the risk of prostate cancer recurrence,” said Allott. …
Lead author, Krasimira Aleksandrova, says: “These data provide additional incentive to individuals, medical professionals and public health authorities to invest in healthy lifestyle initiatives. …
How this happens used to be the stuff of science fiction. …
“Cdk4/6 inhibitors used in cancer treatment don’t differentiate between the two molecules. The effectiveness of blocking both proteins at once has not been demonstrated to date,” explains Malumbres…
The study was led by Dr. Jordan Karlitz, Division of Gastroenterology at Tulane University School of Medicine who is also adjunct faculty at the LSU Health New Orleans School of Public Health, Dr. Xiao-Cheng Wu, Professor of Public Health and Director of the LSU Health New Orleans Louisiana Tumor Registry, Dr…